D
BridgeBio Pharma, Inc. BBIO
$32.19 -$0.82-2.48%
Recommendation
Sell
Prev Close
$33.01
Volume
1,942,133
Avg Vol (90D)
2,731,066
Market Cap
$6.28B
Dividend & Yield
--
52-Week Range
$21.62 - $39.47
P/E (TTM)
--
EPS (TTM)
-$2.85
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D
Weak
Rating Factors
Growth Index
Fair
Efficiency Index
Very Weak
Solvency Index
Fair
Total Return Index
Fair
Volatility Index
Weak
Dividend Index
--
Headlines
BridgeBio Pharma appoints Thomas Trimarchi as CFO
3/17/2025 - Seeking Alpha - Healthcare
BridgeBio Announces CFO Succession
3/17/2025 - Globe Newswire
Charles Schwab Investment Management Inc. Buys 21,963 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)
3/17/2025 - MarketBeat
Monimus Capital Management LP Makes New $1.13 Million Investment in BridgeBio Pharma, Inc. (NASDAQ:BBIO)
3/16/2025 - MarketBeat
BridgeBio Pharma (BBIO, $32.59) Stochastic Oscillator left the oversold zone on March 12, 2025
3/13/2025 - Tickeron - Stocks
Analysts' Top Healthcare Picks: BridgeBio Pharma (BBIO), Vertex Pharmaceuticals (VRTX)
3/11/2025 - TipRanks Financial Blog
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Major Shareholder Genetic Disorder L.P. Kkr Sells 6,000,000 Shares
3/8/2025 - MarketBeat
J.P. Morgan Sticks to Their Buy Rating for BridgeBio Pharma (BBIO)
3/8/2025 - TipRanks Financial Blog
BridgeBio Pharma (NASDAQ:BBIO) Shares Gap Down - Here's What Happened
3/7/2025 - MarketBeat
BridgeBio Pharma (BBIO, $32.23) price exceeded its 50-day Moving Average on March 06, 2025
3/7/2025 - Tickeron - Technical Analysis
BridgeBio Pharma (BBIO, $32.23) price exceeded its 50-day Moving Average on March 06, 2025
3/7/2025 - Tickeron - Stocks
The 4.5% return this week takes BridgeBio Pharma's (NASDAQ:BBIO) shareholders three-year gains to 308%
3/6/2025 - Simply Wall St
Sum Up The Parts: GUSA Could Be Worth $60
3/5/2025 - ETF Channel
BridgeBio Pharma (BBIO, $33.01) Stochastic Oscillator left the oversold zone on March 03, 2025
3/4/2025 - Tickeron - Stocks
BridgeBio Pharma (BBIO, $33.01) entered Downtrend as Momentum indicator drops below 0 level on Mar 03, 2025
3/4/2025 - Tickeron - Stocks
Prediction: BridgeBio Pharma Will Beat the Market. Here's Why
3/4/2025 - Fool.com Headlines
BridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Neil Kumar Sells 75,000 Shares
3/2/2025 - Ticker Report
Y Intercept Hong Kong Ltd Increases Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO)
3/1/2025 - MarketBeat
Brian C. Stephenson Sells 8,500 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) Stock
3/1/2025 - MarketBeat
BridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Neil Kumar Sells 75,000 Shares
3/1/2025 - MarketBeat
BridgeBio Pharma Strengthens Financial Position with Note Issuance
2/28/2025 - TipRanks Financial Blog
BridgeBio Pharma's cancer-focused spinout plans $450 million deal to go public
2/28/2025 - BizJournals.com - Nat'l Business News
BridgeBio Pharma, Inc. (NASDAQ:BBIO) CFO Sells $282,115.00 in Stock
2/28/2025 - MarketBeat
BridgeBio Pharma (NASDAQ:BBIO) Sees Strong Trading Volume - Time to Buy?
2/27/2025 - MarketBeat
BridgeBio Pharma (BBIO, $33.45) Moving Average Convergence Divergence (MACD) Histogram turned negative on February 26, 2025
2/27/2025 - Tickeron - Stocks
Income Statement
Total Revenue (TTM)
$221.90M
EBITDA (TTM)
-$571.29M
EBIT (TTM)
-$577.37M
Net Income (TTM)
-$535.76M
Balance Sheet
Total Assets (Q)
$919.34M
Total Debt (Q)
$1.73B
Total Liabilities (Q)
$2.38B
Book Value Per Share (Q)
-$7.72
Cash Flow
Cash from Operations (TTM)
-$520.73M
Cash from Investing (TTM)
$60.78M
Cash from Financing (TTM)
$748.46M
Net Change in Cash (TTM)
$288.51M
Filings
Filing Date
Thursday, February 20, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Beginning of May (est)
Price History
Loading...
Beta
1.94
7-Day Total Return
1.96%
30-Day Total Return
3.74%
60-Day Total Return
15.71%
90-Day Total Return
27.74%
Year to Date Total Return
14.15%
1-Year Total Return
15.75%
2-Year Total Return
129.93%
3-Year Total Return
188.96%
5-Year Total Return
99.81%
52-week Low
Jun 24, 2024 - $21.62
52-week High
Feb 20, 2025 - $39.47
Valuation
Market Cap
$6.28B - Mid Cap
Enterprise Value
$7.34B
Price/Sales (TTM)
28.18
Price/Book (Q)
-4.27
Dividends and Shares
Shares Outstanding
189.44M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
bridgebio.com
Phone Number
650 391 9740
Address
3160 Porter Drive
Palo Alto, CA 94304
Country
United States
Year Founded
2015
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and... more
NASDAQ 03/18/2025 4:00PM Eastern Quotes delayed
Weiss Ratings